EGFR and neoplasm: Grisanti et al. [35] observed in patients with locally advanced and recurrent metastatic head and neck cancer (32% of the oral cavity) that EGFR expression could be modulated over time, with the presence of EGFR at any time point being low (45%) when compared with the primary tumour, which could identify cancer cells that were more likely to metastasize.